Esther de Viuda García-rekin lankidetzan egindako argitalpenak (8)

2024

  1. Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis

    Menopause (New York, N.Y.), Vol. 31, Núm. 3, pp. 234-242

2023

  1. Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  2. Population-based survey on menopausal symptoms and treatment use

    Climacteric, Vol. 26, Núm. 1, pp. 47-54

2022

  1. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group

    Maturitas, Vol. 166, pp. 65-85

2021

  1. Health-related quality of life and resilience in peri- and postmenopausal women during Covid-19 confinement

    Maturitas, Vol. 144, pp. 4-10

2020

  1. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia

    Maturitas, Vol. 137, pp. 57-62

  2. Response to “Should estrogen be used in the co-treatment of COVID-19 patients?”

    Maturitas

  3. The thromboembolic risk in covid-19 women under hormonal treatment group

    Maturitas